Imaging Agent Meets Criteria for Phase 3 Completion
Lantheus Medical Imaging announced that an interim analysis of the first of two Phase 3 studies has met the criteria for completion for its Phase 3 flurpiridaz F 18 clinical program. Flurpiridaz F 18 injection is a fluorine 18-labeled agent that binds to mitochondrial complex 1 (MC-1). It was designed to be a myocardial perfusion PET imaging agent to evaluate patients with known or suspected CAD.
The Phase 3 clinical development program includes two trials in about 1,400 patients at clinical trial sites in North America and Europe. The primary objective is to assess myocardial perfusion using Positron Emission Tomography (PET) imaging with flurpiridaz F 18 in patients with known or suspected coronary artery disease (CAD). The first of the two Phase 3 studies has passed the interim analysis assessment milestone and should be completed later in the year. So far approximately 900 subjects have been imaged with flurpiridaz F 18.
For more information call (800) 362-2668 or visit www.lantheus.com.